세계의 동물용 원료의약품 제조 시장 규모, 점유율, 동향 분석 : 동물별, 서비스별, 합성법별, 치료 영역별, 지역별, 부문별 예측(2025-2033년)

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Summary

The global veterinary active pharmaceutical ingredients manufacturing market size was estimated at USD 9.33 billion in 2024 and is projected to reach USD 17.36 billion by 2033, growing at a CAGR of 7.24% from 2025 to 2033. The industry is growing due to rising investments in outsourcing, R&D of new veterinary products, the expanding livestock industry, and expenditure on animal health.

Pharmaceutical companies increasingly outsource animal health API production to specialized contract manufacturing organizations (CMOs) to reduce costs, improve efficiency, and access advanced manufacturing capabilities. This outsourcing enables firms to focus on R&D and marketing of pharmaceuticals. This surges the demand for high-quality APIs having faster production timelines and enhanced scalability. For instance, in November 2024, SeQuent Scientific and Viyash Lifesciences approved a strategic merger, creating a global animal health leader with integrated capabilities, 16 manufacturing facilities, strong R&D, and access to over 150 international markets. This merger is poised to strengthen their global presence, enhance innovation through manufacturing and deliver comprehensive solutions across the animal healthcare industry.

In addition, rising investments in research and development by companies to create innovative APIs, including novel medications and biologics are boosting market growth. R&D focuses on efficacy, safety, and regulatory compliance, enabling differentiation in a competitive market. This leads to the development of high-value, specialized APIs, improved animal health outcomes, and enhanced market competitiveness.

The surge in livestock numbers for meat, dairy, and poultry production, combined with increasing pet populations, has propelled the need for animal health medications. Higher populations lead to more disease susceptibility, requiring vaccines, anti-infectives, and supportive drugs. Manufacturers respond by producing larger volumes of APIs and expanding production facilities. The effect is a robust demand pipeline for APIs, stimulating innovation, technological adoption, and strategic collaborations.

Furthermore, increasing veterinary healthcare spending, driven by higher disposable income, growing pet ownership, and livestock industry expansion, raises demand for preventive and therapeutic medications. According to the American Pet Products Association report, in 2024, USD 152 billion was spent on pets for food, medicines, vet care products and other services. This surge in spending has driven higher production and consumption of veterinary APIs, encouraging manufacturers to expand operations, adopt advanced technologies, and develop innovative products to meet growing market demand. Higher expenditure encourages investment in quality control, innovation, and regulatory compliance. Thus, rising animal health expenditure directly fuels the expansion and competitiveness of the veterinary API manufacturing market.

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary active pharmaceutical ingredients manufacturing market report based on service, synthesis, animal, therapeutic category, and region.

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Companion Animals
• Production Animals
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• In House
• Contract Outsourcing
  • Contract Development
  • Preclinical Development
  • Clinical Development
  • Contract Manufacturing
• Synthesis Outlook (Revenue, USD Million, 2021 - 2033)
• Chemical Based API
• Biological API
• HPAPI
• Therapeutic Category Outlook (Revenue, USD Million, 2021 - 2033)
• Antiparasitics
• Anti-infectives
• NSAIDs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Synthesis
  • 1.2.3. Animal
  • 1.2.4. Therapeutic Category
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Investments in Outsourcing
    • 3.2.1.2. R&D Of New Veterinary Products
    • 3.2.1.3. Expanding Livestock Industry
    • 3.2.1.4. Expenditure on Animal Health
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory Compliance and High Production Costs
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: By Animal Estimates & Trend Analysis

• 4.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal: Segment Dashboard
• 4.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Movement Analysis
• 4.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 4.4. Companion Animals
  • 4.4.1. Companion Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Production Animals
  • 4.5.1. Production Animals Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: By Service Estimates & Trend Analysis

• 5.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service: Segment Dashboard
• 5.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Movement Analysis
• 5.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates & Forecasts, by Service, 2021 to 2033 (USD Million)
• 5.4. In House
  • 5.4.1. In House Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.5. Contract Outsourcing
  • 5.5.1. Contract Outsourcing Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.2. Contract Development
    • 5.5.2.1. Contract Development Market Estimates and Forecasts, 2021 - 2033(USD Million)
    • 5.5.2.2. Preclinical Development
      • 5.5.2.2.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033(USD Million)
    • 5.5.2.3. Clinical Development
      • 5.5.2.3.1. Clinical Development Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.3. Contract Manufacturing
    • 5.5.3.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: By Synthesis Estimates & Trend Analysis

• 6.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis: Segment Dashboard
• 6.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Movement Analysis
• 6.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates & Forecasts, by Synthesis, 2021 to 2033 (USD Million)
• 6.4. Chemical-based API
  • 6.4.1. Chemical-based API Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.5. Biological API
  • 6.5.1. Biological API Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.6. HPAPI
  • 6.6.1. HPAPI Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: By Therapeutic Category Estimates & Trend Analysis

• 7.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category: Segment Dashboard
• 7.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category Movement Analysis
• 7.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates & Forecasts, by Therapeutic Category, 2021 to 2033 (USD Million)
• 7.4. Antiparasitics
  • 7.4.1. Antiparasitics Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 7.5. Anti-infectives
  • 7.5.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 7.6. NSAIDs
  • 7.6.1. NSAIDs Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 8. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Alivira Animal Health Ltd.
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Ofichem Group
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Chempro Pharma Pvt. Ltd.
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Siflon Drugs
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Qilu Animal Health Products Co., Ltd.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Vetpharma
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. SUANFARMA
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. MENADIONA
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Excel Industries Ltd.
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives